JeanMarie Guenot is a Mover and Shaker when it comes to Pharmaceutical Development

 

According to her bio, JeanMarie Guenot holds a Master’s of Business Administration (MBA) from the Wharton School of Business at the University of Pennsylvania and a Doctor of Philosophy (Ph.D.) from the University of California at San Francisco. Dr. Guenot received her training in medical and physical chemistry and focused on semi-empirical and quantum mechanical methods for protein structure prediction, NMR refinement. drug design and molecular dynamics.

 

She began her career with Atlas Ventures and was the manager of capital investments. She took on the challenge of building life science companies. Her career in science began when she took on the role of principal scientist at Hoffman-La Roche in preclinical research and development. Her work as principal scientist included drug development for oncology and inflammation issues, autoimmune diseases and metabolic diseases. Dr. Guenot was the founder of SKS Ocular, an ophthalmic company start-up and made her focus sustained release drug delivery technology and therapeutics for ocular inflammation, macular degeneration and glaucoma.

 

Dr. JeanMarie Guenot is currently the President and Chief Executive Officer (CEO) of Amphivena Therapeutics, Inc., (AT). Dr. Guenot has been in the biotechnology and pharmaceutical industry for more than 20 years and has been involved in the venture capital industry, alliance and project management and business development. All her accrued experience has made her the perfect fit for her role at Amphivena Therapeutics, Inc.

Amphivena Therapeutics, Inc. was founded in 2012 and provides drug development services. The focus of the company is to develop pharmaceuticals for treating hematological tumors. Her role is to provide leadership for the development team to continue its work in the development of pharmaceuticals. Currently, Amphivena Therapeutics, Inc. is on the forefront of developing pharmaceuticals for acute myeloid leukemia (AML) treatment. The drug therapy will follow new drug protocol of clinical study and evaluation.

 

Several years ago, Jeanmarie Guenot and Amphivena Therapeutics, Inc., established an agreement with Janssen Biotech, Inc., and through the agreement, Janssen has exclusive rights to acquire Amphivena Therapeutics, Inc., following IND approval. Janssen paid Amphivena Therapeutics, Inc., an undisclosed sum and will provide additional payments based on certain milestones. The payments are in exchange for the rights to acquire at Janssen’s sole discretion.

Follow Jeanmarie personally on her FB page: https://www.facebook.com/jeanmarie.guenot.9